Cargando…
Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
Immunotherapy with immune checkpoint inhibitors (ICIs), while ameliorating lung cancer, can cause infectious diseases, including tuberculosis, in addition to immune-related noninfectious complications. In the clinical setting, the efficacy of ICIs to treat mycobacterial infection remains controversi...
Autores principales: | Fujita, Kohei, Yamamoto, Yuki, Kanai, Osamu, Okamura, Misato, Nakatani, Koichi, Mio, Tadashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066797/ https://www.ncbi.nlm.nih.gov/pubmed/32190712 http://dx.doi.org/10.1093/ofid/ofaa067 |
Ejemplares similares
-
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020) -
Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021) -
Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017) -
Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Imakita, Takuma, et al.
Publicado: (2021) -
Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
por: Kanai, Osamu, et al.
Publicado: (2021)